Abstract: The present disclosure relates to various different types of mutations in the thrA gene in E. coli leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: The present disclosure relates to various different types of mutations in the thrA gene in E. coli leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: Genetically-modified cell capable of producing UD CA, cholic acid, and/or another UDCA precursor comprising at least one heterologous polynucleotide encoding an enzyme involved in a metabolic pathway that converts sugar to UDCA, cholic acid, and/or another UDCA precursor. Method of making UDCA, cholic acid, and/or another UDCA precursor using such a cell. Use of UDCA or UDCA precursor produced using such a method for the manufacture of a medicament for the treatment of a disease or symptom of a disease. Medicament comprising UDCA or UDCA precursor made using such a method. Method of treating a disease or symptom of a disease comprising administering UDCA or a UDCA precursor made using such a method. Isolated nucleic acid encoding at least one enzyme involved in a metabolic pathway that converts sugar to UDCA, cholic acid, and/or another UDCA precursor.

Abstract: The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: The present disclosure relates to various different types of mutations in S. cerevisiae leading to enhanced tyrosine production for, e.g., supplements and nutraceuticals.

Abstract: The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

Abstract: The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (?)-2-[(R)-(diphenyl-methyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides variant fatty acyl-CoA reductase (FAR) enzymes, polynucleotides encoding the variant FAR enzymes, and vectors and host cells comprising the same.

Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides variant fatty acyl-CoA reductase (FAR) enzymes, polynucleotides encoding the variant FAR enzymes, and vectors and host cells comprising the same.

Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides variant fatty acyl-CoA reductase (FAR) enzymes, polynucleotides encoding the variant FAR enzymes, and vectors and host cells comprising the same.

Abstract: The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (?)-2-[(R)-(diphenyl-methyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides variant fatty acyl-CoA reductase (FAR) enzymes, polynucleotides encoding the variant FAR enzymes, and vectors and host cells comprising the same.

Abstract: A chair with a chair back pivotally attached to a seat. The chair back can be moved from a collapsed position located directly adjacent the seat to an upright position. When in the upright position, a spring biased latch assembly attached to chair seat allows engagement with the chair back and can be adjusted to several, adjustable positions selected by the user. In addition to providing a range of adjustment, this latch system also provides structural integrity to the design of the pivoting chair invention.

Abstract: A chair with a chair back pivotally attached to a seat. The chair back can be moved from a collapsed position located directly adjacent the seat to an upright position. When in the upright position, a spring biased latch assembly attached to chair seat allows engagement with the chair back and can be adjusted to several, adjustable positions selected by the user. In addition to providing a range of adjustment, this latch system also provides structural integrity to the design of the pivoting chair invention.

Abstract: A chair with a chair back pivotally attached to a seat. The chair back can be moved from a collapsed position located directly adjacent the seat to an upright position. When in the upright position, a spring biased latch assembly attached to chair seat allows engagement with the chair back and can be adjusted to several, adjustable positions selected by the user. In addition to providing a range of adjustment, this latch system also provides structural integrity to the design of the pivoting chair invention.

Abstract: A system and method configured to provide secure Personal Identification Number (PIN) based authentication is disclosed. A passcode or PIN associated with a customer value card can be securely authenticated by an issuer prior to authorizing payment. An Access Control Server (ACS) can receive the PIN or passcode from a customer via a secure connection over a public network. The ACS can generate an encrypted PIN and can communicate the encrypted PIN to a remote issuer for authentication. The ACS can use one or more hardware security modules to generate the encrypted PIN. The hardware security modules can be emulated in software or implemented in hardware. The system can be configured such that the PIN is not exposed in an unencrypted form in a communication link or in hardware other than the originating customer terminal.